CFTR and cystic fibrosis: While advances in small molecule CFTR modulator therapies have improved protein function for many mutations (1–3), ∼10% of people with CF cannot benefit from these strategies (4), including those with nonsense and splicing mutations that prevent complete synthesis of CFTR protein.